Your PML stats are wrong. Check page 14 of this link:

//library.corporate-ir.net/library/14/148/148682/items/278364/Q4-07%20Earnings%20Slides.pdf

The safety information lists 0 (zero) patients at 1 year of therapy until Dec 2007. The reference to trials does not include the trials for approval but the trials that were started upon Tysabri reintroduction.

You are also misinformed about the us TOUCH program. Part of the program is the screening for putting the proper patients on the drug. The more important part is the monthly pre-infusion checklist to monitor for any new or worsening symptoms. Let's see PML in 1 out of 19500 Tysabri patients in the US (with TOUCH) while there's been PML in 3 out of 16000 Tysabri patients in Europe. Seems like TOUCH could be making a difference.

Clearly you think you know and are correct about everything regarding Tysabri so there isn't much point in discussing this further.

Chris